The Science Behind Ketamine — How It Actually Works
Medically reviewed and authored by Dr. David Mahjoubi, MD — Board-Certified Anesthesiologist · President, American Board of Ketamine Physicians (ABKP) · Author of The Art & Science of Ketamine Medicine · Prescribing and administering ketamine since 2014.
Last reviewed: June 2026
Why most pages on "the science of ketamine" don't actually explain the science
If you’ve spent any time researching ketamine therapy online, you’ve probably read a lot of pages that promise to explain how ketamine works and then don’t. They use phrases like “rewires the brain” or “resets your neurochemistry” without telling you what’s actually happening at the molecular level. They cite “the latest research” without naming a single study. They tell you ketamine is “FDA-approved since 1970” without explaining why that 50-year safety record matters for someone considering at-home treatment in 2026.
This page is the opposite of that. I’m going to walk you through:
- What ketamine actually does in the brain — the receptors, the cascade, the structural changes you can see on imaging
- Why standard antidepressants fail 40–60% of patients, and what ketamine does differently
- The published evidence base, named by author, year, and journal — so you can look any of it up
- How the mechanism differs by condition — depression, PTSD, chronic pain, anxiety, OCD
- How NutraBrain Clinic applies all of this in practice — including real follow-up data from our own patients and our forthcoming UCLA research collaboration
I’ve spent 17 years prescribing and administering this drug, in operating rooms and intensive care units before mental-health applications, and in clinics and at-home telehealth for treatment-resistant depression, anxiety, PTSD, OCD, and chronic pain since 2014. I authored The Art & Science of Ketamine Medicine, the only physician-authored ketamine treatment manual in print. I serve as President of the American Board of Ketamine Physicians.
Let’s get to the science.
1. Why standard antidepressants fail many patients
To understand why ketamine works, you first have to understand why the standard antidepressant ladder doesn’t, for a substantial fraction of patients.
Selective serotonin reuptake inhibitors (SSRIs) — Lexapro, Zoloft, Prozac, Paxil, Celexa — were developed on the serotonin hypothesis of depression. The idea, dominant from the 1980s through the 2010s, was that depression is caused by a deficiency of serotonin in the synapse between neurons. Raise serotonin, the theory went, and depression should lift.
The serotonin hypothesis has not held up well.
In 2022, Moncrieff and colleagues published an umbrella review in Molecular Psychiatry aggregating decades of evidence on the serotonin theory of depression. Their conclusion: “the main areas of serotonin research provide no consistent evidence” of a serotonin abnormality in depression. The headline finding was that the simple chemical-imbalance story most patients were taught is not supported by the science.
That doesn’t mean SSRIs don’t work for anyone. They do work for some patients. But here’s what the data actually shows about their limits:
- The STAR*D trial — the largest real-world study of sequential antidepressant treatment, sponsored by the NIH — found that roughly one-third of patients failed to achieve remission even after four sequential antidepressant trials.
- Time to response is slow: most SSRIs require 4 to 6 weeks of consistent use before benefit emerges, and that’s if benefit emerges at all.
- Side effects drive discontinuation: emotional blunting (reported by up to 60% of long-term SSRI users in surveys by Goodwin and colleagues), sexual dysfunction, weight gain, and sleep disruption are common reasons patients stop taking the medication that’s supposedly helping them.
This is the gap ketamine fills. Not for every patient — but for many of the patients SSRIs were never going to help.
2. How ketamine actually works — the mechanism, explained
Ketamine acts on a completely different neurotransmitter system than SSRIs. SSRIs work on serotonin. Ketamine works on glutamate — the brain’s primary excitatory neurotransmitter, the chemical messenger that handles nearly all rapid, signal-by-signal neural communication.
Here’s what happens, step by step, when ketamine reaches the brain.
Step 1 — NMDA receptor blockade
Ketamine is an NMDA receptor antagonist. NMDA receptors are a type of glutamate receptor present on many neurons, including a population called GABAergic interneurons — small neurons whose job is to inhibit other neurons. When ketamine blocks the NMDA receptors on these inhibitory interneurons, it takes the brakes off the larger neurons they were inhibiting.
Step 2 — Glutamate surge
With the brakes off, the larger excitatory neurons fire freely. The result is a paradoxical transient surge of glutamate release in regions of the brain critical to mood regulation, particularly the medial prefrontal cortex. Counterintuitively, blocking a glutamate receptor produces more glutamate signaling overall, because the receptor was on a neuron whose job was to suppress the rest of the system.
Step 3 — AMPA receptor activation and BDNF
The increased glutamate floods the synapses and activates a different glutamate receptor, the AMPA receptor. AMPA activation triggers a downstream signaling cascade — specifically, it activates mTORC1 (mammalian target of rapamycin complex 1), a master regulator of protein synthesis in neurons. mTORC1 activation, in turn, drives the synthesis of brain-derived neurotrophic factor (BDNF), sometimes described as a fertilizer for neurons. BDNF promotes the growth, survival, and connectivity of brain cells.
Step 4 — Synaptogenesis and dendritic spine growth
Within hours of a ketamine dose, BDNF triggers the formation of new synapses and new dendritic spines — the small protrusions on neurons where most synaptic connections are made. This has been directly observed in animal studies and is increasingly being demonstrated in human imaging.
Step 5 — The neuroplasticity window
The end result is a 24- to 72-hour window of heightened neuroplasticity — a brief period during which the brain is unusually capable of reorganizing itself. This is the window that explains:
- Why ketamine produces an antidepressant effect within hours, not weeks
- Why it can reduce suicidal ideation rapidly, often within a single session
- Why patients describe a sense of “perspective” or “lifting” they hadn’t experienced in years
- Why pairing ketamine sessions with psychotherapy within that window often produces durable change
3. The published evidence base — actual studies, by author and year
This is where most websites about ketamine therapy stop and start handwaving. I’m going to do the opposite. Here are the studies that built the evidence base for ketamine as a psychiatric treatment.
Foundational depression trials
Mechanism studies
PTSD
Suicidality
Real-world at-home outcomes
Regulatory validation
You can look any of these up on pubmed.ncbi.nlm.nih.gov. The evidence base is real, published, peer-reviewed, and accumulating.
4. How ketamine's mechanism applies to different conditions
The basic NMDA → glutamate → BDNF → neuroplasticity cascade is the same regardless of condition. What changes is which circuits the increased plasticity affects and which therapeutic outcome matters.
For treatment-resistant depression
The neuroplasticity window targets the medial prefrontal cortex (mPFC) — the executive-control region that, in depression, becomes underactive and loses its ability to regulate emotional responses arising from deeper limbic structures. Increased dendritic spine density in mPFC restores executive top-down control. Patients commonly describe a return of “perspective” — the ability to recognize a depressive thought as a thought, rather than as truth. Read more about ketamine for treatment-resistant depression.
For PTSD
Same mechanism, different clinical target. PTSD is a disorder of stuck traumatic memory — the amygdala stays hyper-vigilant, the hippocampus underperforms at contextualizing the memory as past rather than present, and the mPFC loses its ability to inhibit the fear response. Ketamine’s neuroplasticity window makes traumatic memories more “movable” — they can be re-examined without overwhelming arousal. Read more about ketamine for PTSD.
For chronic pain
The mechanism is partially different. In chronic pain — particularly neuropathic pain, fibromyalgia, and complex regional pain syndrome (CRPS) — the central nervous system becomes pathologically over-responsive to pain signals through a process called central sensitization. Sub-perceptual ketamine doses appear to reduce central sensitization by acting on NMDA receptors in the spinal cord and brain. Counterintuitively, for pain, low daily microdoses often work better than high dissociative-dose sessions. This is one of the most important lessons I’ve learned over 17 years. Read more about ketamine for chronic pain.
For anxiety
The mechanism overlaps with depression — restoration of mPFC executive control over limbic anxiety responses. The clinical signature is different: patients describe a quieting of constant background anxiety and increased capacity to face situations they had been avoiding. Read more about ketamine for anxiety.
For OCD
The intrusive-thought patterns characteristic of OCD appear to weaken during the neuroplasticity window. Multiple small studies (Rodriguez et al., Bloch et al.) have documented this. The evidence base is younger than for depression but consistent.
For postpartum depression
The FDA recently approved zuranolone (an oral GABA-A modulator) specifically for postpartum depression, validating the broader idea that rapid-acting antidepressants are clinically distinct from SSRIs. Ketamine has a smaller but growing evidence base in postpartum populations and is used in NutraBrain practice in consultation with the patient’s OB/GYN.
5. Real-world outcomes from NutraBrain patients
Published trials are important. Real-world data from actual telehealth practice is also important — and the depth of the NutraBrain practice is one of the things that distinguishes it from venture-backed companies that have only been operating a few years. We’ve been administering ketamine therapy since 2014. Below is the de-identified aggregate from a recent analysis of 36 patients who completed our structured 2-week follow-up.
| Measure | Result |
|---|---|
| Mean overall patient satisfaction (1–5) | 4.78 |
| Mean rating of communication and information clarity (1–5) | 4.86 |
| Mean rating of staff professionalism (1–5) | 4.83 |
| (1–5) | 4.81 |
| Patients reporting clinical side effects | 0% |
| Patients indicating desire to continue treatment | 100% |
In their own words, patients spontaneously described the treatment using phrases like “life-saving,” “wonderful improvement,” and providing “tremendous help” for the conditions they came to us for. Of the patients who provided detailed clinical feedback, 100% said they wanted to continue — the only exits from the program in the analyzed cohort were patients moving to a state where we do not currently hold a license.
These numbers are consistent with the response rates documented in the published literature. They are also consistent with what 17 years of practicing this specialty has taught me: when ketamine works, it tends to work clearly and quickly, and patients tell you about it.
6. Active research and the next chapter
NutraBrain × UCLA Research Collaboration
NutraBrain Clinic is preparing to participate in a forthcoming large-scale clinical research study in collaboration with Dr. Robert Ashley at the University of California, Los Angeles (UCLA).
The study will systematically measure clinical outcomes for at-home ketamine therapy across a substantially larger patient cohort than has been studied in most published telehealth-ketamine work to date, using validated symptom scales including the PHQ-9 (Patient Health Questionnaire) and the GAD-7 (Generalized Anxiety Disorder scale) — the standard instruments used in modern psychiatric research.
Why this matters for patients and for the field:
- Real-world outcomes data, at scale. The published literature on ketamine for depression, PTSD, and chronic pain is strong, but the largest randomized trials have been done in academic in-clinic settings rather than at-home telehealth. Building the at-home outcomes evidence base is one of the most important next steps for the specialty.
- Academic partnership. Collaboration with UCLA researchers adds independent scientific oversight to NutraBrain’s clinical practice and connects our patient population to the broader academic ketamine research community.
- A standard the rest of the at-home category has avoided. Most telehealth ketamine companies do not publish peer-reviewed outcomes data from their own practices. NutraBrain Clinic intends to.
Going forward, NutraBrain will publish quarterly outcomes summaries on this page incorporating PHQ-9 and GAD-7 response rates from our patient cohort, building toward the larger UCLA collaboration.
7. How NutraBrain applies all of this in practice
The science only matters if it changes what your doctor actually does. Here’s how the mechanism described above translates to NutraBrain protocols.
- Dr. Mahjoubi personally evaluates every patient. Every NutraBrain patient meets and works with Dr. Mahjoubi directly — not with rotating nurse practitioners. The first 30–45 minute consult is with him. Email access between sessions is with him.
- Format selection matches the condition. For depression and anxiety, nasal spray or sublingual troches — both with sub-anesthetic dosing. For PTSD, sublingual troches are favored for the longer therapeutic window that allows more emotional processing. For chronic pain, daily microdose lozenges at sub-perceptual doses often outperform high-dose sessions.
- Dose calibrated to response, not to a package. Most at-home programs use a fixed 6-session protocol regardless of how the patient is responding. NutraBrain does not. Some patients reach durable improvement in 3 sessions. Some need 8 to 10. Some do best on continuous low-dose microdosing without any high-dose sessions at all.
- The exclusive ketamine + oxytocin formulation. For patients with relational disconnection, attachment trauma, or chronic SSRI-induced emotional blunting, the NutraBrain compounded ketamine + oxytocin nasal spray addresses both the mood and the bonding/attachment circuitry. It is the only such formulation in U.S. telehealth.
- Maximum dosing ceiling of 1,400 mg/week. Most at-home programs cap dosing far below this. Higher ceiling matters for chronic pain protocols and for patients whose body weight or metabolism requires higher doses to reach therapeutic effect.
- Medication interactions are reviewed honestly. Benzodiazepines blunt ketamine’s neuroplastic effect — we usually have patients hold them around session days. Cannabis attenuates antidepressant response — we discuss this directly with patients who use it. Most providers don’t address either issue.
- Integration is encouraged, not assumed. The durability of a patient’s response depends substantially on what they do in the 24–72 hour neuroplasticity window after each session. Therapy, journaling, time with people who matter to them, reflection on what came up in session. Pairing ketamine with continued psychiatric or therapeutic care is something we recommend, not avoid.
Frequently asked questions about the science
-
SSRIs raise serotonin in the synapse. Ketamine blocks NMDA receptors, which triggers a glutamate surge, downstream BDNF release, and rapid synaptogenesis. Two completely different mechanisms, two different timelines (weeks vs. hours), two different kinds of clinical response.
-
Not in the classical sense. Psilocybin and LSD work primarily on serotonin 2A receptors. Ketamine works on NMDA receptors. The "trip" or dissociation people describe during a ketamine session is a dose-dependent dissociative effect, not a serotonergic psychedelic effect. At therapeutic sub-anesthetic doses, the dissociation is mild and is itself the intended therapeutic effect.
-
Because the mechanism is different. SSRIs work through slow downstream adaptation to elevated synaptic serotonin. Ketamine triggers direct, rapid synaptogenesis through the BDNF / mTORC1 pathway. Hours vs. weeks reflects the difference between rapid neuroplasticity and slow neuro-adaptation.
-
Brain-derived neurotrophic factor. A protein the brain uses to grow and maintain neurons. BDNF levels are reduced in chronic depression. Ketamine acutely raises BDNF and drives synaptogenesis. Higher BDNF and more synaptic connectivity in the medial prefrontal cortex correlate with antidepressant response.
-
No. Studies that have separated the dissociative experience from the antidepressant effect — using midazolam (which produces sedation and some dissociation) as an active control — have shown that ketamine's antidepressant effect is mechanistically distinct from its acute subjective effects.
-
Because the doses are completely different. Therapeutic at-home doses are 5 to 15 times smaller than surgical anesthesia doses. At sub-anesthetic doses, ketamine preserves airway reflexes and breathing — which is why we use it in ICUs and battlefield medicine. The pharmacological safety margin at sub-anesthetic doses is large.
-
Usually yes. SSRIs and SNRIs are generally compatible. Benzodiazepines (Xanax, Klonopin, Ativan) blunt ketamine's neuroplastic effect — we typically have patients hold them around session days. MAOIs are contraindicated. Your full medication list is reviewed at your initial consult.
-
Yes. Chronic cannabis use is associated with reduced antidepressant response to ketamine and often requires dose adjustment. We discuss this honestly with patients who use cannabis. It is not a moral judgment; it is a pharmacological observation that affects the protocol.
Want to find out if at-home ketamine therapy may be right for you?
Three free ways to start.
NutraBrain Clinic serves patients in Arizona, California (excluding Los Angeles and Orange Counties), Connecticut, Florida, Illinois, Massachusetts, New Jersey, New Mexico, New York, Texas, Utah, Virginia, and Wisconsin. If you live in LA or Orange County, please visit www.phos.la.
